| Title: | Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension |
| Journal: | European Journal of Human Genetics |
| Published: | 14 Dec 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/38097766/ |
| DOI: | https://doi.org/10.1038/s41431-023-01518-2 |
| URL: | https://eprints.lancs.ac.uk/id/eprint/212359/1/oc_paper_text_clean_oct27_AL.pdf |
| Citations: | 1 (1 in last 2 years) as of 8 Aug 2024 |
Publication 9171
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
CYP2A6 is a polymorphic enzyme that inactivates nicotine; structural variants (SVs) include gene deletions and hybrids with the neighboring pseudogene CYP2A7. Two studies found that CYP2A7 deletions were associated with ovarian cancer risk. Using their methodology, we aimed to characterize CYP2A6 SVs (which may be misidentified by prediction software as CYP2A7 SVs), then assess CYP2A6 SV-associated risk for ovarian cancer, and extend analyses to lung cancer. An updated reference panel was created to impute CYP2A6 SVs from UK Biobank array data. Logistic regression models analyzed the association between CYP2A6 SVs and cancer risk, adjusting for covariates. Software-predicted CYP2A7 deletions were concordant with known CYP2A6 SVs. Deleterious CYP2A6 SVs were not associated with ovarian cancer (OR = 1.06; 95% CI: 0.80-1.37; p = 0.7) but did reduce the risk of lung cancer (OR = 0.44; 95% CI: 0.29-0.64; p < 0.0001), and a lung cancer subtype. Replication of known lung cancer associations indicates the validity of array-based SV analyses.</p>
5 Authors
- Alec W. R. Langlois
- Jennie G. Pouget
- Jo Knight
- Meghan J. Chenoweth
- Rachel F. Tyndale
Enabling scientific discoveries that improve human health